Busulfan: all 322 studies that test it

Page 1 of 4. Open to participants first (42), then studies with results posted, then the rest; newest registration first within each.

• 26DT052; Scaling Busulfan Dose to Body Surface Area in ChildrenNot yet recruitingNCT07792369Phase 1
• Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIMEnrolling by invitationNCT07775313Phase 1/2
• A Study of VABu Conditioning Regimen in Allo-HSCT for AML PatientsNot yet recruitingNCT07762508Not applicable
• Haplo-Cord HSCT for AML/MDSRecruitingNCT07588360Not applicable
• Cord Blood Transplantation in Children and Young Adults With Blood CancerRecruitingNCT07566377Phase 2
• TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete RemissionNot yet recruitingNCT07563920Not applicable
• Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersNot yet recruitingNCT07524530Phase 2
• The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood TransplantationNot yet recruitingNCT07441967Phase 2
• Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous DiseaseEnrolling by invitationNCT07113743Phase 1/2
• Reduced Intensity Conditioning for MDSNot yet recruitingNCT07085156Phase 2
• Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient StudyRecruitingNCT06959771Phase 1/2
• Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Not yet recruitingNCT06954987Phase 2
• Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid LeukemiaRecruitingNCT06869265Phase 2
• Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene TherapyEnrolling by invitationNCT06851767Phase 1/2
• Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT06809712Phase 1
• Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT06809699Phase 1
• Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)RecruitingNCT06802315Phase 2
• Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous DiseaseRecruitingNCT06325709Phase 1/2
• Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDSRecruitingNCT06247917Phase 2
• The Optimization of Conditioning Regimen for HLA Matched HSCT in SAARecruitingNCT06069180Phase 4
• Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid MalignanciesRecruitingNCT05991908Phase 3
• MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesRecruitingNCT05735717Phase 2
• CD34+ Enriched Transplants to Treat Myelodysplastic SyndromeNot yet recruitingNCT05617625Not applicable
• Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBLRecruitingNCT05598593Phase 2
• CD34+ Transplants for Myeloid MalignanciesNot yet recruitingNCT05565105Phase 2
• MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingNCT05564390Phase 2
• ChiCGB vs BEAM in High-risk or R/R LymphomasRecruitingNCT05466318Phase 3
• Allogeneic Hematopoietic Stem Cell Transplantation for 4/M NeuroblastomaNot yet recruitingNCT05303727Phase 2
• Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSRecruitingNCT04708054Phase 2/3
• Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant DisordersRecruitingNCT04644016Phase 2
• Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative ConditioningNot yet recruitingNCT04451200Phase 2
• High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)RecruitingNCT04221035Phase 3
• Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)RecruitingNCT03970096Phase 2
• Alpha/Beta TCD HCT in Patients With Inherited BMF DisordersRecruitingNCT03579875Phase 2
• Autologous Gene Therapy for Artemis-Deficient SCIDRecruitingNCT03538899Phase 1/2
• Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)RecruitingNCT03126916Phase 3
• Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell LymphomasRecruitingNCT02859402Phase 2
• Personalized NK Cell Therapy in CBTRecruitingNCT02727803Phase 2
• HSCT for Patients With Fanconi Anemia Using Risk-Adjusted ChemotherapyRecruitingNCT02143830Phase 2
• Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic LeukaemiaRecruitingNCT01949129Phase 2/3
• Allogeneic Hematopoietic Stem Cell Transplant for GATA2 MutationsRecruitingNCT01861106Phase 2
• Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)RecruitingNCT01306019Phase 1/2
• Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.TerminatedNCT05579769Phase 2Results posted
• Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or DysregulationActive, not recruitingNCT03663933Phase 2Results posted
• Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched DonorsTerminatedNCT03615105Phase 2Results posted
• A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi AnemiaTerminatedNCT03600909Phase 2Results posted
• Allogeneic Stem Cell Transplantation for Multiple Myeloma and MyelofibrosisTerminatedNCT03303950Phase 2Results posted
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
• Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCTCompletedNCT03018223Phase 1Results posted
• Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCIDCompletedNCT02999984Phase 1/2Results posted
• HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation CyclophosphamideCompletedNCT02793544Phase 2Results posted
• Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)CompletedNCT02766465Phase 2Results posted
• Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC SubtypeTerminatedNCT02589145Phase 1/2Results posted
• MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCsCompletedNCT02582775Phase 2Results posted
• Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple MyelomaCompletedNCT02506959Phase 2Results posted
• JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary MyelofibrosisCompletedNCT02251821Phase 2Results posted
• Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and MyelodysplasiaCompletedNCT02007863Not applicableResults posted
• Therapy for Children With Advanced Stage NeuroblastomaCompletedNCT01857934Phase 2Results posted
• Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA GeneCompletedNCT01852071Phase 1/2Results posted
• Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesCompletedNCT01823198Phase 1/2Results posted
• Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk NeuroblastomaCompletedNCT01798004Phase 1Results posted
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic MalignanciesCompletedNCT01760655Phase 2Results posted
• Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow TransplantationTerminatedNCT01749293Phase 2Results posted
• CHOEP + High Dose Therapy + Auto SCT for T-Cell LymphomaTerminatedNCT01746173Phase 2Results posted
• Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 InfectionCompletedNCT01734850Phase 1/2Results posted
• Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT01701986Phase 1/2Results posted
• Busulfan and Cyclophosphamide Followed By ALLO BMTTerminatedNCT01685411Not applicableResults posted
• Busulfan/Clofarabine + Allogeneic Stem Cell TransplantationCompletedNCT01643668Phase 2Results posted
• Allogeneic Stem Cell Transplant for CLLTerminatedNCT01629511Phase 1/2Results posted
• T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic TransplantTerminatedNCT01621477Phase 2Results posted
• Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01605032Phase 2Results posted
• Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine ConditioningCompletedNCT01572662Phase 2Results posted
• High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell TransplantTerminatedNCT01534143Phase 2Results posted
• Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic MalignanciesCompletedNCT01499147Not applicableResults posted
• A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple MyelomaCompletedNCT01413178Phase 3Results posted
• Allogeneic Transplant in HIV Patients (BMT CTN 0903)CompletedNCT01410344Phase 2Results posted
• Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATGCompletedNCT01390402Phase 2Results posted
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological MalignanciesCompletedNCT01384513Phase 2Results posted
• Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) DeficiencyCompletedNCT01380990Phase 1/2Results posted
• Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body IrradiationTerminatedNCT01366612Phase 3Results posted
• Cord Blood Transplantation for Patients With CancerTerminatedNCT01359254Phase 2Results posted
• Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)TerminatedNCT01339910Phase 3Results posted
• A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell DiseaseTerminatedNCT01279616Phase 2Results posted
• Umbilical Cord Blood Transplant for Children With Myeloid Hematological MalignanciesCompletedNCT01247701Not applicableResults posted
• High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk MyelomaCompletedNCT01237951Phase 2Results posted
• Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic TransplantationCompletedNCT01203020Phase 2Results posted
• High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's DiseaseCompletedNCT01200329Phase 2Results posted
• Tandem Auto-Allo Transplant for LymphomaCompletedNCT01181271Phase 2Results posted
• Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With IsotretinoinCompletedNCT01175356Phase 1Results posted
• Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid LeukemiaCompletedNCT01168219Phase 2Results posted
• Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic CancersTerminatedNCT01135329Phase 2Results posted
• Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte InfusionsCompletedNCT01131169Phase 2Results posted
• HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic MalignanciesCompletedNCT01119066Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell TransplantTerminatedNCT01118013Phase 2Results posted
• Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01093586Phase 2Results posted
• Allogeneic Bone Marrow Transplant for Inherited Metabolic DisordersCompletedNCT01043640Phase 2Results posted
• Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01027000Phase 2Results posted
• IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma PatientsCompletedNCT01009840Phase 2Results posted
• Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT00990249Phase 2Results posted
• Umbilical Cord Blood Transplant for Congenital Pediatric DisordersCompletedNCT00950846Not applicableResults posted

← Busulfan overview